Peptio

Semax vs Selank: what the evidence separates

Semax and Selank compared on what was measured: small Russian studies, no head-to-head clinical trial, one shared fMRI study and different FDA histories.

Peptio Research

On this page7

Semax and Selank are two different peptides, and no study comparing them in patients was found. Both rest on small, mostly Russian studies, and none of the patient studies described below has an abstract that describes random allocation and blinding against placebo with a clinical outcome. The only study found that gave both to people scanned 52 healthy participants by fMRI, a brain imaging method, and measured resting-state connectivity, not memory, attention or anxiety 1. Its abstract describes "general and specific effects of Selank and Semax" and does not rank one above the other.

Side by side

Semax Selank
Sequence MEHFPGP TKPRPGP
Described as analogue of the ACTH 4-10 fragment synthetic analogue of tuftsin
Studied in patients stroke, eye disease, motor neuron disease, peptic ulcer, posthypoxic encephalopathy anxiety disorders and neurasthenia; blood from patients with depression in one laboratory study
Best design found in patients comparisons not described as randomised; one open-label; some uncontrolled comparisons with a benzodiazepine, no placebo arm
In healthy people fMRI only fMRI only, in the shared study
FDA advisory committee considered 24 July 2026; briefing weighs against the 503A list; HHS states the committee voted in favour on no agenda found
HHS enforcement policy, October 2026 semax free base covered for compounders under ten conditions; not an approval not covered
FDA withdrawn-nominations table listed listed
Russian registration reported by FDA, second hand not established

Each row is sourced in the sections below.

What each is

Semax is a chain of seven amino acids, Met-Glu-His-Phe-Pro-Gly-Pro, as FDA's briefing gives it 2. Published studies describe it as an analogue of the 4-10 fragment of adrenocorticotropic hormone (ACTH), the pituitary hormone that drives cortisol release 3.

Selank is also seven amino acids, Thr-Lys-Pro-Arg-Pro-Gly-Pro 4. It is a synthetic analogue of tuftsin, a four-amino-acid fragment of the human immunoglobulin G heavy chain, lengthened by Pro-Gly-Pro 5.

That Pro-Gly-Pro tail is what the two share. The rest of the sequence differs, and so does the starting peptide: a hormone fragment in one case, an immunoglobulin fragment in the other.

What was measured in people

Semax

In 110 patients after ischaemic stroke, a comparison whose abstract does not describe randomisation reported higher plasma BDNF, a neurotrophic factor measured in blood, and better Barthel index scores of daily living with semax added to rehabilitation; the abstract gives no effect sizes 6. Earlier studies, of 30 stroke patients against 80 controls and of 187 patients with cerebrovascular insufficiency and no stated comparator, report faster recovery on neurological scales the abstracts do not name 7 8.

In 27 people with motor neuron disease, an open-label study found no effect on needle EMG or two ALS rating scales, and better scores only on ALSAQ-40, a patient-reported quality of life questionnaire 9. In people with refractory peptic ulcer, healing at day 14 was reported in 89.5% with semax added to standard drugs against 30.8% on standard drugs alone, in an abstract that gives no sample size or allocation method 10. Russian studies in eye disease report better visual acuity, visual field or electrophysiological measures, mostly with semax added to other treatment 11 12.

In healthy people, the placebo-controlled work measured brain networks by fMRI. In 24 healthy volunteers, 10 of them on placebo, Lebedeva and colleagues report a larger medial frontal part of the default mode network, a set of brain regions active at rest 13. No abstract found tested memory or attention against placebo in healthy people.

Selank

Selank has been tested in four small Russian studies of patients with anxiety disorders, none with a placebo arm 14 15 16 17. In 62 patients with generalised anxiety disorder or neurasthenia, selank (30 patients) and the benzodiazepine medazepam (32 patients) were scored on the Hamilton, Zung and CGI scales, and the authors call the anxiolytic effects "similar" 14. In 60 patients with phobic-anxiety and somatoform disorders, a comparison with phenazepam reports "mild nootropic effects" of selank without naming a cognitive test, and gives no result for phenazepam 15.

In 70 patients with anxiety-phobic, hypochondriac and somatoform disorders, selank added to phenazepam (40) against phenazepam alone (30) is reported to bring forward improvement on the HDRS and to reduce phenazepam's side effects on the UKU scale 16. That design tests selank alongside a benzodiazepine, not on its own. The fourth study measured immune laboratory markers, not symptoms 17.

The one study that included both

Panikratova and colleagues scanned 52 healthy participants given selank, semax or placebo, before and 5 and 20 minutes after administration, and report differences in functional connectivity of the right amygdala 1. No anxiety, memory or attention measure was reported, and the abstract does not state arm sizes, randomisation or blinding.

FDA's briefing notes that the semax participants in this study and in the earlier 24-person fMRI study "appear to be very similar" and that it is unclear whether the same people took part in both 2. The two samples are not added together here.

FDA

FDA lists both in its table of bulk drug substances nominated for compounding but withdrawn, with separate wording for each. For semax it states the agency "lacks sufficient information to know whether the drug would cause harm if administered to humans"; for selank acetate it states that FDA "lacks important information regarding any safety issues raised by selank acetate administered to humans" 18. Neither has an entry in any category of the 503A bulk drug substance list updated on 14 May 2026 19.

The histories then diverge. FDA's Pharmacy Compounding Advisory Committee considered semax free base and semax acetate on 24 July 2026 for cerebral ischaemia, migraine and trigeminal neuralgia 20. FDA's briefing concludes that "a balancing of the criteria weighs against" placing semax on the 503A list, resting "in particular" on semax not being well characterised physicochemically, and finds that the two references it could assess "demonstrated lack of effectiveness" for those uses 2. A trade journal and a law firm, both second hand, report that the committee nonetheless voted to recommend semax for the list, without giving the count; FDA had posted no vote record by 6 November 2026 20, and a recommendation does not put a substance on the list 21. HHS's October 2026 enforcement policy says the committee voted in favour, and that HHS does not intend to act against compounders of semax free base, for intranasal use, who meet ten listed conditions 22. The notice calls that policy a non-binding draft 23. Selank is not among its six substances 22. Selank was not on the July 2026 agenda or on the one FDA lists for before the end of February 2027, and no FDA briefing on selank was found 20 24.

On Russian registration, FDA's briefing states that "Semax is a registered drug in Russia", citing the Russian State Register; this site could not retrieve the register entry 2. For selank, the only source found is a table in a 2022 review that lists it as an anxiolytic among peptide drugs developed in Russia, without a registration number, date or indication, so its registration is not established here 25. Registration in Russia, where reported, is not approval elsewhere.

What is not known

Searches found no registered trial and no systematic review for either peptide. No placebo-controlled study with a clinical outcome was found in patients for either, and no study was found that compared the two on memory, attention, anxiety or any other clinical endpoint. The claim that semax improves memory and attention in healthy people traces, in the sources found, to a 1997 overview by its developers that names no test or sample size 26. The claim that selank acts on GABA-A receptors is a hypothesis in the sources found: in rat frontal cortex, selank or GABA changed the expression of 45 genes, with no count for selank alone, while a human cell line showed no change 5 27.

On the evidence found, the two cannot be ranked against each other for any outcome in people.

Peptides covered

Research areas

Sources

  1. 1. Panikratova YR et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady Biological Sciences. 2020. PubMed 32342318
  2. 2. FDA Briefing Document: Semax-Related Bulk Drug Substances (Semax (free base) and Semax acetate), Pharmacy Compounding Advisory Committee, July 23-24, 2026. U.S. Food and Drug Administration. 2026. View source(open access)
  3. 3. Dolotov OV et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006. PubMed 16996037
  4. 4. Zozulya AA et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine. 2001. PubMed 11550013
  5. 5. Volkova A et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2016. PubMed 26924987(open access)
  6. 6. Gusev EI et al. [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2018. PubMed 29798983
  7. 7. Gusev EI et al. [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 1997. PubMed 11517472
  8. 8. Gusev EI, Skvortsova VI, Chukanova EI. [Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2005. PubMed 15792140
  9. 9. Serdiuk AV et al. [The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2007. PubMed 18379501
  10. 10. Ivanikov IO et al. Therapy of peptic ulcer with semax peptide. Bulletin of Experimental Biology and Medicine. 2002. PubMed 12459874
  11. 11. Nazarova GA et al. [The results of the application of the pre-formed physical factors and neuroprotective therapy for the rehabilitative treatment of the patients with diabetic retinopathy]. Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury. 2013. PubMed 24437205
  12. 12. Dragon AK et al. [Results of the application of complex physiotherapeutic neurostimulation in optical neuropathies of various genesis]. Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury. 2022. PubMed 36083821
  13. 13. Lebedeva IS et al. Effects of Semax on the Default Mode Network of the Brain. Bulletin of Experimental Biology and Medicine. 2018. PubMed 30225715
  14. 14. Zozulia AA et al. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2008. PubMed 18454096
  15. 15. Medvedev VE et al. [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2014. PubMed 25176261
  16. 16. Medvedev VE et al. [Optimization of the treatment of anxiety disorders with selank]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2015. PubMed 26356395
  17. 17. Uchakina ON et al. [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2008. PubMed 18577961
  18. 18. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026. View source(open access)
  19. 19. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, updated May 14, 2026. U.S. Food and Drug Administration. 2026. View source(open access)
  20. 20. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. 2026. View source(open access)
  21. 21. Crossan SS, Watkins S. Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions. Holland & Knight Alert. 2026. View source(open access)
  22. 22. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B. U.S. Department of Health and Human Services. 2026. View source(open access)
  23. 23. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, 91 FR 68526). Federal Register. 2026. View source(open access)
  24. 24. Meeting of the Pharmacy Compounding Advisory Committee (to be scheduled before the end of February 2027). U.S. Food and Drug Administration. 2026. View source(open access)
  25. 25. Deigin VI et al. Development of Peptide Biopharmaceuticals in Russia. Pharmaceutics. 2022. PubMed 35456550(open access)
  26. 26. Asmarin IP et al. [A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study)]. Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova. 1997. PubMed 9173745
  27. 27. Filatova E et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in Pharmacology. 2017. PubMed 28293190(open access)